The Trillium II Prize
12 February 2019
Posted by: Heather Smith
A prize for the health organization that best uses and promotes the FHIR International Patient Summary (IPS).
The Trillium II Prize will award the health organisation that, in the opinion of the panel of judges, has done the most to use and promote FHIR International Patient Summary (IPS) for international medical information exchanges.
What is FHIR IPS?
An International patient summary (IPS) document is an electronic health record extract containing essential healthcare information intended for use in the unscheduled, cross-border care scenario, comprising at least the required elements of the IPS dataset. The IPS dataset is a minimal and non-exhaustive patient summary dataset, specialty-agnostic, condition-independent, but readily usable by clinicians for the cross-border unscheduled care of a patient..
Trillium II builds on previous recommendations to put IPS standards at the core of a global community for digital health innovation, with the aim of advancing patient safety and trust by bridging the gap between strategic intent and capability to deliver interoperability at a global scale.
The prize was formally announced at the Connected Health Conference 2018 event in Boston - USA, on 17th October 2018. The competition will close on 1st May 2019 and the winners will be announced at an appropriate event in Europe a month thereafter. Furthermore, in addition to the promotional benefits from winning the prize, there will be a cash award of €1,000.
A judging panel composed of experts from different organization and from academia all around Europe will select the winners:
Kathi Apostolidis, President - Hellenic Cancer Federation-ELL.O.K.
Elaine Blechman, CEO, Prosocial Applications, Inc. and Professor Emerita, University of Colorado
Christopher Chute, Chief Research Information Officer for Johns Hopkins Medicine
Gora Data, Group Chairman, CAL2CAL Corporation
Marc Lange, Secretary General, European Health Telematics Association (EHTEL), Belgium
Jeremy Thorp, Director of Business Architecture, NHS UK
Mike Short, Chief Scientific Adviser, Department for International Trade, UK
Depending on the level of interest in the prize, a subcommittee of Trillium partners Alexander Berler, Catherine Chronaki, Charles Lowe and Janne Rasmussen may select a shortlist of entries for the above to judge.
Shortlist selection will be based on the following award criteria:
• Conformance to the specification;
• Ease of interface to EHRs/PHRs (input and output);
• Numbers and types of patients/persons for whom an IPS was generated;
• Ease of access by patient while abroad;
• Options for download, redistribution, sharing, directing;
• Benefit realisation and anticipated future impact.
We are especially keen for SMEs and not-for-profits to apply, although any organisation, other than the participants in the Trillium II consortium, can enter the competition. Partnerships may enter, though only if one organisation in the partnership accepts the lead role.
Registration and application details
All candidates are required to send a registration request to MedCom (Lene Taustrup, email@example.com) in order to ensure that they have immediate access to the online registration form and all the updates to the definition of the IPS, and other relevant data that are produced during the competition period, so that they are working from a level playing field. Entries should be in English only.
In the online form the following information must be provided according to the following format:
- Applicant details – name, organisation, address including country, other contact details, organisation type, ultimate organisation owner/s.
- Organisational role – how your organisation can use the IPS to improve international healthcare delivery; who you have worked with to do this (if any other organisation(s). Max 300 words
- IPS implementation details – how you have put the IPS to use; the type of healthcare service you are using it in; the specifics of the application. Max 300 words.
- Results – what the results have been so far, ideally quantitively in terms of people affected, benefit received and improved patient outcomes, including who has verified the results, otherwise qualitatively. Max 300 words.
- The future – extrapolate into the future what benefits your use of the ILS will deliver – please give a rationale and justification for your projection so the judges can decide how likely it is to happen. Max 300 words
All the key documents relevant to the IPS that have been finalised to date are available for download.
For more information please contact Charles Lowe at firstname.lastname@example.org and follow the official hashtag #TrilliiumIIPrize.